Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Kushen Injection combined with single-agent chemotherapy in elderly patients with advanced non-small cell lung cancer
ChiCTR-IPR-14005484Phase 4Recruiting
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Oct 2014
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of compound kushen injection in non-small cell lung cancer (NSCLC) (2 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoints: Disease control rate, Objective response rate and 1 more. Started Oct 2014; status: recruiting.
02
Drugs
compound kushen injection
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-IPR-14005484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005484.